Leuprolide acetate: a drug of diverse clinical applications

Bibliography

• SCHALLY AV, ARIMURA A, KASTIN AJ et al.: Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones. Science (1971) 173:1036-1038.
   PubMed Web of Science ®Google Scholar
• SCHALLY AV, ARIMURA A, BABA Y et al.: Isolation and properties of the FSH and LH-releasing hormone. Biochem. Biophys. Res. Commun. (1971) 43:393-399.
   PubMed Web of Science ®Google Scholar
• REDDING TW, SCHALLY AV: Inhibition of prostate tumor growth in two rat models by chronic administration of D-Trp6 analogue of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA (1981) 78:6509-6512.
   PubMed Web of Science ®Google Scholar
• GILLATT D: Antiandrogen treatments in locally advanced prostate cancer: are they all the same? J. Cancer Res. Clin. Oncol. (2006) 132(Suppl 1):S17-S26.
   PubMed Web of Science ®Google Scholar
• SCHALLY AV, REDDING TW, COMARU-SCHALLY AM: Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate (1983) 4:545-552.
   PubMed Web of Science ®Google Scholar
• SCHALLY AV, COMARU-SCHALLY AM, PLONOWSKI A, NAGY A, HALMOS G, REKASI Z: Peptide analogs in the therapy of prostate cancer. Prostate (2000) 45:158-166.
   PubMed Web of Science ®Google Scholar
• HOFFMANN G, SPITZ J, BEHRENS R: GnRH-agonists in the therapy of endometriosis. Ther. Umsch (1990) 47:937-944.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN AJ, BARBIERI RL, BENACERRAF BR, SCHIFF I: Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist. Fertil. Steril. (1987) 48:560-564.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN AJ, HARRISON-ATLAS D, BARBIERI RL, BENACERRAF B, GLEASON R, SCHIFF I: A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil. Steril. (1989) 51:251-256.
   PubMed Web of Science ®Google Scholar
• LEE PA, PAGE JG: Effects of leuprolide in the treatment of central precocious puberty. J. Pediatr. (1989) 114:321-324.
   PubMed Web of Science ®Google Scholar
• TANAKA T, HIBI I, KATO K et al.: A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP study group. Endocrinol. Jpn (1991) 38:369-376.
   PubMedGoogle Scholar
• BOWEN RL, VERDILE G, LIU T et al.: Luteinizing hormone, a reproductive regulator that modulates the processing of amyloid-β precursor protein and amyloid-β deposition. J. Biol. Chem. (2004) 279:20539-20545.
   PubMed Web of Science ®Google Scholar
• ATWOOD CS, MEETHAL SV, LIU T et al.: Dysregulation of the hypothalamic-pituitary-gonadal axis with menopause and andropause promotes neurodegenerative senescence. J. Neuropathol. Exp. Neurol. (2005) 64:93-103.
   PubMed Web of Science ®Google Scholar
• CASADESUS G, WEBBER KM, ATWOOD CS et al.: Luteinizing hormone modulates cognition and amyloid-β deposition in Alzheimer APP transgenic mice. Biochim. Biophys. Acta (2006) 1762:447-452.
   PubMed Web of Science ®Google Scholar
• MUENSTERMANN U, KLEINSTEIN J: Long-term GnRH analogue treatment is equivalent to laparoscopic laser diathermy in polycystic ovarian syndrome patients with severe ovarian dysfunction. Hum. Reprod. (2000) 15:2526-2530.
   PubMed Web of Science ®Google Scholar
• BAHCECI M, ULUG U, BEN-SHLOMO I, ERDEN HF, AKMAN MA: Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study. J. Reprod. Med. (2005) 50:84-90.
   PubMed Web of Science ®Google Scholar
• AWADALLA SG, FRIEDMAN CI, CHIN NW, DODDS W, PARK JM, KIM MH: Follicular stimulation for in vitro fertilization using pituitary suppression and human menopausal gonadotropins. Fertil. Steril. (1987) 48:811-815.
   PubMed Web of Science ®Google Scholar
• TAY CC: Use of gonadotrophin-releasing hormone agonists to trigger ovulation. Hum. Fertil. (Camb) (2002) 5:G35-G37; discussion G38-G39, G41-G38.
   Google Scholar
• MATHIAS JR, FERGUSON KL, CLENCH MH: Debilitating ‘functional’ bowel disease controlled by leuprolide acetate, gonadotropin-releasing hormone (GnRH) analog. Dig. Dis. Sci. (1989) 34:761-766.
   PubMed Web of Science ®Google Scholar
• BALDUCCI R, TOSCANO V, MANGIANTINI A et al.: Adult height in short normal adolescent girls treated with gonadotropin-releasing hormone analog and growth hormone. J. Clin. Endocrinol. Metab. (1995) 80:3596-3600.
   PubMed Web of Science ®Google Scholar
• MEZROW G, SHOUPE D, SPICER D, LOBO R, LEUNG B, PIKE M: Depot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome. Fertil. Steril. (1994) 62:932-937.
   PubMed Web of Science ®Google Scholar
• NILLIUS SJ: Luteinizing hormone releasing hormone analogues for contraception. Clin. Obstet. Gynaecol. (1984) 11:551-572.
   PubMedGoogle Scholar
• LABRIE F, SEGUIN C, BELANGER A et al.: Contraception with LHRH agonists, a new physiological approach. Reproduccion (1981) 5:229-241.
   PubMedGoogle Scholar
• CORBIN A: From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J. Biol. Med. (1982) 55:27-47.
   PubMed Web of Science ®Google Scholar
• SCHALLY AV: Contraceptive potential of analogs of LH-RH. Network (1984) 6:7-8.
   PubMedGoogle Scholar
• ALLEN JM, O'SHEA JP, MASHITER K, WILLIAMS G, BLOOM SR: Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist. Br. Med. J. (Clin. Res. Ed.) (1983) 286:1607-1609.
   PubMed Web of Science ®Google Scholar
• WELLINGTON K, KEAM SJ: Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer. Drugs Aging (2007) 24:169-171.
   PubMed Web of Science ®Google Scholar
• DINEEN MK, TIERNEY DS, KUZMA P, PENTIKIS HS: An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer. J. Clin. Pharmacol. (2005) 45:1245-1249.
   PubMed Web of Science ®Google Scholar
• SCHLEGEL PN: Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer. J. Urol. (2006) 175:1353-1358.
   PubMed Web of Science ®Google Scholar
• WAXMAN JH, SANDOW J, ABEL P et al.: Two-monthly depot gonadotropin releasing hormone agonist (buserelin) for treatment of prostatic cancer. Acta Endocrinol. (Copenh.) (1989) 120:315-318.
   PubMedGoogle Scholar
• CONN PM, CROWLEY WF Jr: Gonadotropin-releasing hormone and its analogs. Ann. Rev. Med. (1994) 45:391-405.
   PubMed Web of Science ®Google Scholar
• ZORN JR, SOUBRANE O, SIBONI O, PAPAGEORGIOU G: Medical reversible castration with D-Trp-6-LH-RH microcapsules for the treatment of endometriosis. Preliminary results in a series of 51 patients. Contrib. Gynecol. Obstet. (1987) 16:254-259.
   PubMedGoogle Scholar
• TOLIS G, ACKMAN D, STELLOS A et al.: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA (1982) 79:1658-1662.
   PubMed Web of Science ®Google Scholar
• JOHNSON CA, THOMPSON DL Jr, CARTMILL JA: Pituitary responsiveness to GnRH in mares following deslorelin acetate implantation to hasten ovulation. J. Anim. Sci. (2002) 80:2681-2687.
   PubMed Web of Science ®Google Scholar
• PATTON ML, BASHAW MJ, DEL CASTILLO SM et al.: Long-term suppression of fertility in female giraffe using the GnRH agonist deslorelin as a long-acting implant. Theriogenology (2006) 66:431-438.
   PubMed Web of Science ®Google Scholar
• HERBERT CA, TRIGG TE, RENFREE MB, SHAW G, ECKERY DC, COOPER DW: Long-term effects of deslorelin implants on reproduction in the female tammar wallaby (Macropus eugenii). Reproduction (2005) 129:361-369.
   PubMed Web of Science ®Google Scholar
• JUNAIDI A, WILLIAMSON PE, CUMMINS JM, MARTIN GB, BLACKBERRY MA, TRIGG TE: Use of a new drug delivery formulation of the gonadotrophin-releasing hormone analogue deslorelin for reversible long-term contraception in male dogs. Reprod. Fertil. Dev. (2003) 15:317-322.
   PubMed Web of Science ®Google Scholar
• PESCOVITZ OH, BARNES KM, CUTLER GB Jr: Effect of deslorelin dose in the treatment of central precocious puberty. J. Clin. Endocrinol. Metab. (1991) 72:60-64.
   PubMed Web of Science ®Google Scholar
• CONN PM: The molecular mechanism of gonadotropin releasing hormone action in the pituitary. In: The Physiology of Reproduction (2nd Edition). Knobil E, Neill JD (Eds), Raven Press, NY, USA (1994):1815-1832.
   Web of Science ®Google Scholar
• MARSHALL JC, DALKIN AC, HAISENLEDER DJ, PAUL SJ, ORTOLANO GA, KELCH RP: Gonadotropin-releasing hormone pulses: regulators of gonadotropin synthesis and ovulatory cycles. Recent Prog. Horm. Res. (1991) 47:155-187; discussion 188-189.
   PubMedGoogle Scholar
• COUNIS R, LAVERRIERE JN, GARREL G et al.: Gonadotropin-releasing hormone and the control of gonadotrope function. Reprod. Nutr. Dev. (2005) 45:243-254.
   PubMedGoogle Scholar
• TERASAWA E: Control of luteinizing hormone-releasing hormone pulse generation in nonhuman primates. Cell Mol. Neurobiol. (1995) 15:141-164.
   PubMed Web of Science ®Google Scholar
• SCHALLY AV, COY DH, ARIMURA A: LH-RH agonists and antagonists. Int. J. Gynaecol. Obstet. (1980) 18:318-324.
   PubMedGoogle Scholar
• REDDING TW, SCHALLY AV: Inhibition of mammary tumor growth in rats and mice by administration of agonistic and antagonistic analogs of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. USA (1983) 80:1459-1462.
   PubMed Web of Science ®Google Scholar
• CLAYTON RN, CATT KJ: Regulation of pituitary gonadotropin-releasing hormone receptors by gonadal hormones. Endocrinology (1981) 108:887-895.
   PubMed Web of Science ®Google Scholar
• MILLAR RP, LU ZL, PAWSON AJ, FLANAGAN CA, MORGAN K, MAUDSLEY SR: Gonadotropin-releasing hormone receptors. Endocr. Rev. (2004) 25:235-275.
   PubMed Web of Science ®Google Scholar
• LIMONTA P, MORETTI RM, MARELLI MM, DONDI D, PARENTI M, MOTTA M: The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology (1999) 140:5250-5256.
   PubMed Web of Science ®Google Scholar
• CHENG KW, LEUNG PC: The expression, regulation and signal transduction pathways of the mammalian gonadotropin-releasing hormone receptor. Can. J. Physiol. Pharmacol. (2000) 78:1029-1052.
   PubMed Web of Science ®Google Scholar
• HARRISON GS, WIERMAN ME, NETT TM, GLODE LM: Gonadotropin-releasing hormone and its receptor in normal and malignant cells. Endocr. Relat. Cancer (2004) 11:725-748.
   PubMed Web of Science ®Google Scholar
• WILSON AC, SALAMAT MS, HAASL RJ et al.: Human neurons express Type I GnRH receptor and respond to GnRH I by increasing luteinizing hormone expression. J. Endocrinol. (2006) 191:651-663.
   PubMed Web of Science ®Google Scholar
• ADAMS TE, CUMMING S, ADAMS BM: Gonadotropin-releasing hormone (GnRH) receptor dynamics and gonadotrope responsiveness during and after continuous GnRH stimulation. Biol. Reprod. (1986) 35:881-889.
   PubMed Web of Science ®Google Scholar
• SENNELLO LT, FINLEY RA, CHU SY et al.: Single-dose pharmacokinetics of leuprolide in humans following intravenous and subcutaneous administration. J. Pharm. Sci. (1986) 75:158-160.
   PubMed Web of Science ®Google Scholar
• PERITI P, MAZZEI T, MINI E: Clinical pharmacokinetics of depot leuprorelin. Clin. Pharmacokinet. (2002) 41:485-504.
   PubMed Web of Science ®Google Scholar
• Drug Facts and Comparisons, Kastrup E (Ed.), Wolters Kluwer St. Louis, WO, USA (2003).
   Google Scholar
• Drug Information Handbook, Lacy C, Armstrong L, Goldman M, Lance L (Eds), Lexi-Comp, Inc., Cleveland, OH, USA (2003).
   Google Scholar
• SCHALLY AV, COMARU-SCHALLY AM, NAGY A et al.: Hypothalamic hormones and cancer. Front. Neuroendocrinol. (2001) 22:248-291.
   PubMed Web of Science ®Google Scholar
• Physicians' Desk Reference (61st Edition). Thomson PDR, Montvale, NJ, USA (2007).
   Google Scholar
• HORNSTEIN MD, SURREY ES, WEISBERG GW, CASINO LA: Leuprolide acetate depot and hormonal add-back in endometriosis: a 12-month study. Lupron add-back study group. Obstet. Gynecol. (1998) 91:16-24.
   PubMed Web of Science ®Google Scholar
• SURREY ES, HORNSTEIN MD: Prolonged GnRH agonist and add-back therapy for symptomatic endometriosis: long-term follow-up. Obstet. Gynecol. (2002) 99:709-719.
   PubMed Web of Science ®Google Scholar
• DREICER R: The evolving role of hormone therapy in advanced prostate cancer. Cleve. Clin. J. Med. (2000) 67:720-722, 725-726.
   PubMed Web of Science ®Google Scholar
• MCLEOD DG: Hormonal therapy: historical perspective to future directions. Urology (2003) 61:3-7.
   PubMed Web of Science ®Google Scholar
• SCHALLY AV, REDDING TW, COMARU-SCHALLY AM: Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat. Rep. (1984) 68:281-289.
   PubMedGoogle Scholar
• SCHALLY AV: Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides (1999) 20:1247-1262.
   PubMed Web of Science ®Google Scholar
• KUHN JM, BILLEBAUD T, NAVRATIL H et al.: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N. Engl. J. Med. (1989) 321:413-418.
   PubMed Web of Science ®Google Scholar
• LIMONTA P, MONTAGNANI MARELLI M, MORETTI RM: LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opin. Investig. Drugs (2001) 10(4):709-720.
   PubMed Web of Science ®Google Scholar
• TRACHTENBERG J, GITTLEMAN M, STEIDLE C et al.: A Phase III, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J. Urol. (2002) 167:1670-1674.
   PubMed Web of Science ®Google Scholar
• CRAWFORD ED: Early versus late hormonal therapy: debating the issues. Urology (2003) 61:8-13.
   PubMedGoogle Scholar
• SCHERR D, PITTS WR Jr, VAUGHN ED Jr: Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J. Urol. (2002) 167:535-538.
   PubMed Web of Science ®Google Scholar
• Treatment and survival of patients with cancer of the prostate. The veterans administration co-operative urological research group. Surg. Gynecol. Obstet. (1967) 124:1011-1017.
   PubMedGoogle Scholar
• BYAR DP: Proceedings: the veterans administration cooperative urological research group's studies of cancer of the prostate. Cancer (1973) 32:1126-1130.
   PubMed Web of Science ®Google Scholar
• BYAR DP, CORLE DK: Hormone therapy for prostate cancer: results of the veterans administration co-operative urological research group studies. NCI Monogr. (1988):165-170.
   PubMedGoogle Scholar
• MALKOWICZ SB: The role of diethylstilbestrol in the treatment of prostate cancer. Urology (2001) 58:108-113.
   PubMed Web of Science ®Google Scholar
• HENRIKSSON P, CARLSTROM K, POUSETTE A et al.: Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen. Prostate (1999) 40:76-82.
   PubMed Web of Science ®Google Scholar
• SCHMITT B, WILT TJ, SCHELLHAMMER PF et al.: Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology (2001) 57:727-732.
   PubMed Web of Science ®Google Scholar
• DUPONT A, CUSAN L, GOMEZ JL et al.: Combination therapy with flutamide and the LHRH agonist [D-Trp6, des-Gly-NH(2)10]LHRH ethylamide in stage C prostatic carcinoma. Br. J. Urol. (1993) 72:629-634.
   PubMedGoogle Scholar
• OLIVE DL, PRITTS EA: Treatment of endometriosis. N. Engl. J. Med. (2001) 345:266-275.
   PubMed Web of Science ®Google Scholar
• PRENTICE A: Regular review: endometriosis. Br. Med. J. (2001) 323:93-95.
   PubMed Web of Science ®Google Scholar
• CROSIGNANI PG, LUCIANO A, RAY A, BERGQVIST A: Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Hum. Reprod. (2006) 21:248-256.
   PubMed Web of Science ®Google Scholar
• DLUGI AM, MILLER JD, KNITTLE J: Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Lupron study group. Fertil. Steril. (1990) 54:419-427.
   PubMed Web of Science ®Google Scholar
• CROSIGNANI PG, GASTALDI A, LOMBARDI PL et al.: Leuprorelin acetate depot versus danazol in the treatment of endometriosis: results of an open multicentre trial. Clin. Ther. (1992) 14(Suppl. A):29-36.
   PubMed Web of Science ®Google Scholar
• WHEELER JM, KNITTLE JD, MILLER JD: Depot leuprolide versus danazol in treatment of women with symptomatic endometriosis. I. Efficacy results. Am. J. Obstet. Gynecol. (1992) 167:1367-1371.
   PubMed Web of Science ®Google Scholar
• WHEELER JM, KNITTLE JD, MILLER JD: Depot leuprolide acetate versus danazol in the treatment of women with symptomatic endometriosis: a multicenter, double-blind randomized clinical trial. II. Assessment of safety. The Lupron endometriosis study group. Am. J. Obstet. Gynecol. (1993) 169:26-33.
   PubMed Web of Science ®Google Scholar
• CHANG SP, NG HT: A randomized comparative study of the effect of leuprorelin acetate depot and danazol in the treatment of endometriosis. Zhonghua Yi Xue Za Zhi (Taipei) (1996) 57:431-437.
   PubMedGoogle Scholar
• RACKOW BW, ARICI A: Options for medical treatment of myomas. Obstet. Gynecol. Clin. North Am. (2006) 33:97-113.
   PubMed Web of Science ®Google Scholar
• COOK JD, WALKER CL: Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin. Reprod. Med. (2004) 22:105-111.
   PubMed Web of Science ®Google Scholar
• SOWTER MC, SINGLA AA, LETHABY A: Pre-operative endometrial thinning agents before hysteroscopic surgery for heavy menstrual bleeding. Cochrane Database Syst. Rev. (2000):CD001124.
   Google Scholar
• PARTSCH CJ, HEGER S, SIPPELL WG: Management and outcome of central precocious puberty. Clin. Endocrinol. (Oxf.) (2002) 56:129-148.
   PubMed Web of Science ®Google Scholar
• COOK JS, DOTY KL, CONN PM, HANSEN JR: Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty. J. Clin. Endocrinol. Metab. (1992) 74:1206-1209.
   PubMed Web of Science ®Google Scholar
• MACCONELL LA, LAWSON MA, MELLON PL, ROBERTS VJ: Activin A regulation of gonadotropin-releasing hormone synthesis and release in vitro. Neuroendocrinology (1999) 70:246-254.
   PubMed Web of Science ®Google Scholar
• CAREL JC, LAHLOU N, JARAMILLO O et al.: Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J. Clin. Endocrinol. Metab. (2002) 87:4111-4116.
   PubMed Web of Science ®Google Scholar
• BADARU A, WILSON DM, BACHRACH LK et al.: Sequential comparisons of one-month and three-month depot leuprolide regimens in central precocious puberty. J. Clin. Endocrinol. Metab. (2006) 91:1862-1867.
   PubMed Web of Science ®Google Scholar
• GENAZZANI AD, PETRAGLIA F, BATTAGLIA C, GAMBA O, VOLPE A, GENAZZANI AR: A long-term treatment with gonadotropin-releasing hormone agonist plus a low-dose oral contraceptive improves the recovery of the ovulatory function in patients with polycystic ovary syndrome. Fertil. Steril. (1997) 67:463-468.
   PubMed Web of Science ®Google Scholar
• FOONG SC, ABBOTT DH, ZSCHUNKE MA, LESNICK TG, PHY JL, DUMESIC DA: Follicle luteinization in hyperandrogenic follicles of polycystic ovary syndrome patients undergoing gonadotropin therapy for in vitro fertilization. J. Clin. Endocrinol. Metab. (2006) 91:2327-2333.
   PubMed Web of Science ®Google Scholar
• DAMARIO MA, BARMAT L, LIU HC, DAVIS OK, ROSENWAKS Z: Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in vitro fertilization outcome in high responder patients. Hum. Reprod. (1997) 12:2359-2365.
   PubMed Web of Science ®Google Scholar
• GEBER S, SALES L, SAMPAIO MA: Comparison between a single dose of goserelin (depot) and multiple daily doses of leuprolide acetate for pituitary suppression in IVF treatment: a clinical endocrinological study of the ovarian response. J. Assist. Reprod. Genet. (2002) 19:313-318.
   PubMed Web of Science ®Google Scholar
• ISIKOGLU M, OZDEM S, BERKKANOGLU M, JAMAL H, SENTURK Z, OZGUR K: Single-dose depot leuprolide is as efficient as daily short-acting leuprolide in ICSI cycles. Hum. Reprod. (2007) 22:1657-1661.
   PubMed Web of Science ®Google Scholar
• ORVIETO R, KERNER R, KRISSI H, ASHKENAZI J, BEN RAFAEL Z, BAR-HAVA I: Comparison of leuprolide acetate and triptorelin in assisted reproductive technology cycles: a prospective, randomized study. Fertil. Steril. (2002) 78:1268-1271.
   PubMed Web of Science ®Google Scholar
• EL A, BHIDE M, KHALIFA Y et al.: Clinical evaluation of three different gonadotrophin-releasing hormone analogues in an IVF programme: a prospective study. Eur. J. Obstet. Gynecol. Reprod. Biol. (2002) 103:140-145.
   PubMed Web of Science ®Google Scholar
• CASADESUS G, WEBBER K, ATWOOD C, BOWEN R, PERRY G, SMITH M: Luteinizing hormone mediates Alzheimer-type changes in neurons. 10th International Conference on Alzheimer's Disease and Related Disorders. Madrid, Spain (15 – 20 July 2006).
   Google Scholar
• BOWEN RL, ISLEY JP, ATKINSON RL: An association of elevated serum gonadotropin concentrations and Alzheimer's disease? J. Neuroendocrinol. (2000) 12:351-354.
   PubMed Web of Science ®Google Scholar
• MATHIAS JR, CLENCH MH, REEVES-DARBY VG et al.: Effect of leuprolide acetate in patients with moderate to severe functional bowel disease. Double-blind, placebo-controlled study. Dig. Dis. Sci. (1994) 39:1155-1162.
   PubMed Web of Science ®Google Scholar
• MATHIAS JR, CLENCH MH, ROBERTS PH, REEVES-DARBY VG: Effect of leuprolide acetate in patients with functional bowel disease. Long-term follow-up after double-blind, placebo-controlled study. Dig. Dis. Sci. (1994) 39:1163-1170.
   PubMed Web of Science ®Google Scholar
• SETJI TL, BROWN AJ: Comprehensive clinical management of polycystic ovary syndrome. Minerva Med. (2007) 98:175-189.
   PubMedGoogle Scholar
• STEINGOLD K, DE ZIEGLER D, CEDARS M et al.: Clinical and hormonal effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovarian disease. J. Clin. Endocrinol. Metab. (1987) 65:773-778.
   PubMed Web of Science ®Google Scholar
• FREEMAN EW, SONDHEIMER SJ, RICKELS K, ALBERT J: Gonadotropin-releasing hormone agonist in treatment of premenstrual symptoms with and without comorbidity of depression: a pilot study. J. Clin. Psychiatry (1993) 54:192-195.
   PubMed Web of Science ®Google Scholar
• HELVACIOGLU A, YEOMAN RR, HAZELTON JM, AKSEL S: Premenstrual syndrome and related hormonal changes. Long-acting gonadotropin releasing hormone agonist treatment. J. Reprod. Med. (1993) 38:864-870.
   PubMed Web of Science ®Google Scholar
• BROWN CS, LING FW, ANDERSEN RN, FARMER RG, ARHEART KL: Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet. Gynecol. (1994) 84:779-786.
   PubMed Web of Science ®Google Scholar
• CAREL JC: Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. Mol. Cell. Endocrinol. (2006) 254-255:226-233.
   PubMed Web of Science ®Google Scholar
• REITER EO: A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: previously published studies from America. Mol. Cell. Endocrinol. (2006) 254-255:221-225.
   PubMed Web of Science ®Google Scholar
• QUINTOS JB, VOGIATZI MG, HARBISON MD, NEW MI: Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. J. Clin. Endocrinol. Metab. (2001) 86:1511-1517.
   PubMed Web of Science ®Google Scholar
• SATOH M, YOKOYA S: Anabolic steroid and gonadotropin releasing hormone analog combined treatment increased pubertal height gain and adult height in two children who entered puberty with short stature. J. Pediatr. Endocrinol. Metab. (2006) 19:1125-1131.
   PubMed Web of Science ®Google Scholar
• SALEH F: A hypersexual paraphilic patient treated with leuprolide acetate: a single case report. J. Sex Marital Ther. (2005) 31:433-444.
   PubMed Web of Science ®Google Scholar
• GEIER DA, GEIER MR: A clinical trial of combined anti-androgen and anti-heavy metal therapy in autistic disorders. Neuro Endocrinol. Lett. (2006) 27:833-838.
   PubMed Web of Science ®Google Scholar
• BOWEN RL, ATWOOD CS: Living and dying for sex. A theory of aging based on the modulation of cell cycle signaling by reproductive hormones. Gerontology (2004) 50:265-290.
   PubMed Web of Science ®Google Scholar
• JOHNSON ES, SEELY JH, WHITE WF, DESOMBRE ER: Endocrine-dependent rat mammary tumor regression: use of a gonadotropin releasing hormone analog. Science (1976) 194:329-330.
   Google Scholar
• RIVIER C, VALE W: Hormonal secretion in male rats chronically treated with [D-Trp6, Pro9-NEt]-LRF. Life Sci. (1979) 25:1065-1074.
   Google Scholar
• DESOMBRE ER, JOHNSON ES, WHITE WF: Regression of rat mammary tumors effected by a gonadoliberin analog. Cancer Res. (1976) 36:3830-3833.
   Google Scholar
• DANGUY A, LEGROS N, HEUSON-STIENNON JA, PASTEELS JL, ATASSI G, HEUSON JC: Effects of a gonadotropin-releasing hormone (GnRH) analogue (A-43818) on 7,12- dimethylbenz(a)anthracene-induced rat mammary tumors. Histological and endocrine studies. Eur. J. Cancer (1977) 13:1089-1094.
   Google Scholar
• NICHOLSON RI, MAYNARD PV: Anti-tumour activity of ICI 118630, a new potent luteinizing hormone-releasing hormone agonist. Br. J. Cancer (1979) 39:268-273.
   Google Scholar
• ROSE DP, PRUITT B: Modification of the effect of a gonadoliberin analog on 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors by hormone replacement. Cancer Res. (1979) 39:3968-3970.
   Google Scholar
• BOWEN RL, SMITH MA, HARRIS PL et al.: Elevated luteinizing hormone expression colocalizes with neurons vulnerable to Alzheimer's disease pathology. J. Neurosci. Res. (2002) 70:514-518.
   Google Scholar
• WEBBER KM, CASADESUS G, ATWOOD CS, BOWEN RL, PERRY G, SMITH MA: Gonadotropins: a cohesive gender-based etiology of Alzheimer disease. Mol. Cell Endocrinol. (2007) 260-262:271-275.
   Google Scholar
• TIEVA A, STATTIN P, WIKSTROM P, BERGH A, DAMBER JE: Gonadotropin-releasing hormone receptor expression in the human prostate. Prostate (2001) 47:276-284.
   Google Scholar